Acorda Therapeutics (ACOR) Income Annual - Discounting Cash Flows
Acorda Therapeutics, Inc.
ACOR (NASDAQ)

* (except for per share items) of USD
Period Ending: LTM
(Last Twelve Months)
2023
12-31
2022
12-31
2021
12-31
2020
12-31
2019
12-31
2018
12-31
2017
12-31
2016
12-31
2015
12-31
2014
12-31
2013
12-31
2012
12-31
2011
12-31
2010
12-30
2009
12-31
2008
12-31
2007
12-31
2006
12-31
2005
12-31
2004
12-31
2003
12-31
Report Filing 2024-04-01 2023-03-15 2022-03-18 2021-03-16 2020-02-28 2019-02-27 2018-03-01 2017-02-27 2016-02-29 2015-02-27 2014-03-03 2013-02-28 2012-02-28 2011-03-01 2010-02-26 2009-03-02 2008-03-14 2007-03-26 2006-03-31 2004-12-31 2003-12-31
Revenue
118 119 129 153 192 471 588 520 493 401 336 306 292 191 54.7 47.8 39.5 27.4 5.15 0.48 0.86
Cost of Revenue
46.0 30.3 40.8 33.5 34.8 99.3 136 108 92.9 80.6 66.6 57.6 66.6 35.5 11.4 11.4 8.36 7.12 5.13 5.30 0.00
Gross Profit
71.6 88.2 88.3 119 158 372 453 411 400 321 270 248 226 155 43.3 36.5 31.1 20.2 0.01 -4.82 0.86
Operating Expenses
94.8 130 166 206 143 334 685 447 366 284 239 223 191 164 125 110 70.6 43.7 34.4 39.9 63.3
Research & Development
5.15 5.80 10.4 23.0 60.1 106 166 203 149 73.5 53.9 53.9 42.1 30.6 34.6 36.6 22.4 12.1 12.9 22.0 34.3
Selling, General and Administrative
89.7 106 124 153 193 172 181 218 206 202 186 169 149 133 89.9 73.3 48.2 31.6 21.5 17.9 0.00
Other Operating Expenses
0.00 18.2 30.8 30.8 -110 55.0 338 26.2 10.9 9.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 29.1
Operating Income
-23.3 -42.0 -77.3 -86.9 14.5 38.5 -233 -36.0 34.0 36.4 30.4 25.6 35.1 -8.43 -81.3 -73.4 -39.4 -23.5 -34.4 -44.8 -62.5
Net Non-Operating Interest
-31.0 -26.4 -30.0 -29.8 -17.7 -18.1 -18.5 -16.2 -15.0 -8.61 -1.50 -1.33 -3.02 -3.35 -2.67 0.00 0.00 0.00 0.00 0.00 0.00
Interest Income
0.53 1.91 0.00 0.82 4.17 3.52 0.14 0.34 0.44 0.67 0.67 0.55 0.55 0.57 1.75 0.00 0.00 0.00 0.00 0.00 0.00
Interest Expense
31.5 28.3 30.0 30.6 21.9 21.6 18.7 16.5 15.5 9.29 2.17 1.88 3.57 3.92 4.41 0.00 0.00 0.00 0.00 0.00 0.00
Equity & Other Income/(Expense)
-242 33.2 -1.74 8.99 -271 0.02 -0.54 9.90 0.41 0.23 0.00 -0.01 -0.02 0.01 -0.02 0.01 0.05 0.08 0.00 0.00 -0.64
Income Before Tax
-296 -35.2 -109 -108 -274 20.4 -252 -42.3 19.4 28.0 28.9 24.3 32.0 -11.8 -83.9 -73.4 -39.4 -23.4 -34.4 -44.8 -63.1
Income Tax Expense
-43.2 30.7 -5.12 -8.07 -1.28 -13.3 -28.5 -6.66 8.31 10.3 12.4 -131 1.41 -0.59 -1.73 0.89 -0.87 0.48 1.12 -0.03 -0.03
Income Attributable to Non-Controlling Interest
0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.98 0.00 0.00 0.00 0.00 0.00 0.59 1.73 0.02 -0.55 0.15 0.00 0.00 -0.64
Net Income
-253 -65.9 -104 -99.6 -273 33.7 -223 -34.6 11.1 17.7 16.4 155 30.6 -11.8 -83.9 -74.3 -38.0 -24.0 -35.5 -44.7 -62.4
Depreciation and Amortization
31.7 32.0 32.5 21.9 25.6 11.5 23.2 21.6 15.0 8.47 7.00 4.66 4.62 3.95 7.69 0.45 -0.66 1.58 1.81 3.07 0.64
EBITDA
8.40 -10.0 -44.8 -65.0 40.2 50.0 -210 -14.4 49.0 44.9 37.4 30.3 39.7 -4.48 -73.6 -73.0 -40.1 -21.9 -32.6 -41.7 -61.8
Earnings Per Share (EPS)
-203.6 -66.90 -195.8 -246.4 -689.4 85.98 -582.7 -91.79 31.42 51.53 49.07 471.2 93.60 -36.82 -266.9 -262.8 -173.7 -157.1 -20,851 -27,182 -38,835
Diluted Earnings Per Share
-203.6 -66.90 -195.8 -246.4 -689.4 85.38 -583.2 -91.79 30.00 50.40 46.80 460.8 91.20 -36.82 -266.9 -262.8 -173.7 -157.1 -20,851 -27,182 -38,835
Weighted Average Shares Outstanding
1.24 0.99 0.53 0.40 0.40 0.39 0.38 0.38 0.36 0.35 0.35 0.34 0.32 0.32 0.31 0.28 0.22 0.15 0.00 0.00 0.00
Diluted Weighted Average Shares Outstanding
1.24 0.99 0.53 0.40 0.40 0.39 0.38 0.38 0.37 0.35 0.35 0.34 0.33 0.32 0.31 0.28 0.22 0.15 0.00 0.00 0.00
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us